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Abstract
Background: Rheumatic fever (RF) and rheumatic heart disease (RHD) cause considerable morbidity and mortality
amongst Australian Aboriginal and Torres Strait Islander populations. Secondary antibiotic prophylaxis in the form of
4-weekly benzathine penicillin injections is the mainstay of control programs. Evidence suggests, however, that
delivery rates of such prophylaxis are poor.
Methods: This qualitative study used semi-structured interviews with patients, parents/care givers and health
professionals, to explore the enablers of and barriers to the uptake of secondary prophylaxis. Data from participant
interviews (with 11 patients/carers and 11 health practitioners) conducted in four far north Queensland sites were
analyzed using the method of constant comparative analysis.
Results: Deficits in registration and recall systems and pain attributed to injections were identified as barriers to
secondary prophylaxis uptake. There were also varying perceptions regarding responsibility for ensuring injection
delivery. Enablers of secondary prophylaxis uptake included positive patient-healthcare provider relationships,
supporting patient autonomy, education of patients, care givers and healthcare providers, and community-based
service delivery.
Conclusion: The study findings provide insights that may facilitate enhancement of secondary prophylaxis delivery
systems and thereby improve uptake of secondary prophylaxis for RF/RHD.
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Abbreviations: CCM, Chronic Care Model; GAS, Group-A streptococcus; LAB, Long-acting intramuscular benzathine
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Background
RF is an auto-immune condition caused by earlier infection
with group-A streptococcus (GAS), a common bacterium
associated with throat and skin infections [1]. RF is associ-
ated with fever and inflammation of the skin (rash), joints
(arthritis), brain (chorea) and heart (carditis). While most
effects of RF are transitory, carditis associated with RF may
lead to permanent damage to heart valves. This chronic
condition is termed RHD. Severe heart valve damage may
necessitate heart surgery with repair or replacement of
affected valves.
RF and RHD result in significant preventable morbidity,
mortality and health care utilisation [2, 3]. In Australia, RF
occurs almost exclusively in Aboriginal and Torres Strait
Islander populations, particularly those living in rural and
remote northern and central Australia [4]. The burden of
RF and RHD in these populations is amongst the highest
documented in the world [5, 6]. Indigenous children aged
4 to 15 years are particularly at risk of RF and of subse-
quently developing RHD [4].
While a single episode of RF can result in permanent
damage to the heart valves, RHD is more likely to
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develop after recurrent episodes of RF [7, 8]. Further-
more, recurrent episodes of RF in an individual who
already has RHD are likely to cause further injury to the
heart valves thereby increasing severity of disease. Re-
current episodes of RF can be prevented by stopping
re-infection with GAS, through the use of regular anti-
biotics (termed secondary prophylaxis). The most ef-
fective method for achieving this is through the use of
four-weekly, long-acting intramuscular benzathine penicil-
lin (LAB) injections [3, 9, 10]. Secondary prophylaxis is a
core component of RF/RHD management strategies [1].
Despite the demonstrated effectiveness of secondary
prophylaxis in preventing recurrent RF [11], delivery can
be challenging. A number of studies have shown that in
many countries uptake of LAB is less than optimal [12].
We have demonstrated that less than 20 % of individuals
in remote Australia who were prescribed secondary
prophylaxis for RF/RHD received ≥80 % of scheduled
doses in a twelve month period; the median number of
doses over the preceding year was only six of a recom-
mended thirteen [13]. These findings imply that many
Indigenous Australians with RF/RHD are left at risk of
avoidable and progressive heart damage due to subopti-
mal delivery of LAB secondary antibiotic prophylaxis.
Addressing low uptake of secondary prophylaxis for
RF/RHD has been identified as a public health priority
in Australia [14]. Nonetheless, understanding the rea-
sons for poor uptake remains limited. A literature review
previously conducted by three of the authors highlights
a lack of high quality evidence relating to initiatives to
improve the delivery of secondary prophylaxis [12]. The
identified lack of evidence provided justification for the
current study. The aim of this study was to gain a better
understanding of the enablers of, and barriers to, the up-
take of secondary prophylaxis by Aboriginal and Torres
Strait Islander people with RF and/or RHD. Improved
understanding of these factors will enable health care
organisations and communities to better identify and
develop strategies to improve uptake.
Methods
Study design
The research team used a qualitative descriptive study
design. This design was chosen as it “is especially amenable
to obtaining straight and largely unadorned (i.e., minimally
theorized or otherwise transformed or spun) answers” [15].
Using a qualitative descriptive study design enabled the re-
searchers to explore and gain understanding of participants’
experiences of secondary prophylaxis and their perspectives
on the enablers and barriers to uptake.
Sample
Participants were snowball sampled through the use of
key informants who had contacts or were working in
health clinics in one or more of the four far north
Queensland communities included in the study. These
communities are geographically remote, have predomin-
antly Aboriginal and Torres Strait Islander populations,
and have a documented high burden of RF and RHD.
Snowball sampling offered a practical method for accessing
‘hard to reach’ populations [16]. Key informants enabled re-
searchers to access study participants in communities
where individuals can be highly mobile (frequently moving
between communities), where cultural sensitivities may
make direct access to potential participants difficult and
where there are inconsistencies in staffing due to both high
staff turnover and a reliance on external staff delivering out-
reach services [17]. Initial study participants in each com-
munity were asked to recommend other participants from
one or more of the following groups:
 Aboriginal and/or Torres Strait Islander individuals
who had been prescribed secondary prophylaxis for
RF/RHD
 parents/care givers of Aboriginal and/or Torres
Strait Islander children prescribed secondary
prophylaxis for RF/RHD
 health professionals who provide treatment to the
above groups
Data generation
Data were generated between October 2013 and February
2014 via face-to-face interviews in four communities
across the Cape York and Torres Strait regions of far
north Queensland, Australia. Interviews followed a semi-
structured format guided by a grand tour question, which
was modified to suit health professional or patient inter-
viewees, as follows: “Tell me about your experiences of
treating/receiving treatment for rheumatic fever and/or
rheumatic heart disease?” Interviews were audio-taped
and professionally transcribed verbatim. All participants
were provided with written information about the study
and informed consent was obtained prior to participating
in the study.
Data analysis
Interview transcripts were imported into NVivo for
MAC data management software version 10.2.1. Analysis
of transcripts was conducted using the method of con-
stant comparative analysis of data to data, data to inci-
dent, incident to incident and incident to category [18].
The first five transcripts were open coded by authors
JCS and PK, and a code-book developed that was then
used to analyze the remainder of the dataset. Codes were
then compared with codes and collapsed into high order
categories. All authors contributed to this process. This
resulted in six key themes, which respectively describe
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health professionals’ and patients’ perspectives of treat-
ing and receiving treatment for RF/RHD.
Results
A total of 24 participants participated in 22 interviews;
one interview was conducted with an adolescent and
their care giver and one interview was conducted simul-
taneously with two health professionals. The audio of
two interviews was inaudible and hence only 20 inter-
views were transcribed; 11 with patients/care givers and
11 with health practitioners.
A number of themes were identified. These are sum-
marized in Table 1 and outlined in more detail below.
Participants’ verbatim quotes are used as evidence to
support findings in each of the six themes.
Case ascertainment/registration/recall systems
Ensuring that patients access diagnostic and treatment
services for RF/RHD is challenging for health services.
Effective disease registers rely on both an efficient and
accurate system for identifying patients requiring ongoing
follow-up (case ascertainment/registration) and systems
for prompting follow-up (reminder/recall). Given that case
ascertainment and registration rely on broader health care
access and systems, the focus of this study was the pro-
cesses associated with follow-up and delivery of secondary
antibiotic prophylaxis.
The use of reminder/recall systems ensures that pa-
tients receive treatment reminders either prior to when
treatments are due or, if the service is not provided in
the relevant timeframe, when they become overdue.
Such reminders can include patient-held reminders
(wallet cards, mobile device applications), direct visits
to a patient’s homes or school, posting of lists in promin-
ent public spaces (e.g., local store), letters or emails. The
health services involved in this study rely on a number of
such systems.
In some instances there is duplication in register systems.
Thus, some services use a combination of a centralized
State based reminder/recall system, regional databases and
local databases. The sharing of registration (who requires
prophylaxis) and service delivery (when prophylaxis was de-
livered) information between different systems creates is-
sues in regards to capturing and accurately recording data.
On the whole, health services included in the study receive
State based patient recall lists from Rheumatic Heart
Disease Queensland, which they cross check with regional
databases to see which patients are due or overdue for sec-
ondary prophylaxis. Once patients receive injections,
health professionals update local, regional and State based
systems. The following health professional’s recount of the
process highlights the complexity of duplicate systems:
Well, RHD Australia, they send out a bicillin recall
list every first week of each month. I print that off the
computer and then with that information I’ve got to go
and sit on MD3 [regional database] and get [the
local] bicillin recall list. Then I’ve got to update the
information off MD3 onto RHD Australia’s recall list
and from there I’ve got to go and sit on my computer
and update my system. […] Once it’s updated – the
RHD Australia recall list, then I fax it back to them or
I can scan it and email it back to them. (P11)
Interviews with health professionals from a health
service in another community further highlight the
complexities of duplicate systems. Health professionals
explained that they use the centralized State-based re-
minder/recall register as “a kind of reminder” (P16),
the health service district’s electronic patient informa-
tion system for managing “all the overdue rheumatic
heart disease” (P16), and a local system, comprising
both a list of overdue patients on a wall-chart and a
staff diary, to record visits to overdue clients:
We go out and give them [overdue patients] invites.
We go to home visits if they haven’t turned up and
we’re continually doing weekly invites. We make sure
that it’s in the diary that’s kept for all staff as a
reminder of who’s going out. (P17)
Pain of injections
Interview data presents a range of strategies used to ad-
dress the pain associated with LAB injections and suggests
that pain remains a deterrent to uptake. Strategies
used to minimize pain include the use of paracetamol-
based pain relief, ice-packs, topical anesthetic creams
and warming the needle. During interview one health
professional also referred to the potential use of anal-
gesic gas, although, at the time of interview this had
not yet been implemented. The health professional
explained:
We’ve got an entonox cylinder and a circuit. We
haven’t yet got a workplace instruction […] we’re
waiting for that to happen and we’re hoping that –
because they use that at the hospital to help improve
the – decrease the amount of distress (P14).
Table 1 Elements of health care delivery relevant to secondary
antibiotic prophylaxis delivery for RF/RHD
1. Case ascertainment/registration/recall systems
2. Pain of injections
3. Locus of responsibility (patient/care giver/clinician)
4. Site of service delivery
5. Education
6. Health professional-patient relationships
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Data relating to pain associated with LAB injections
reveals a number of differing perspectives. From the per-
spective of health professionals, pain is generally consid-
ered to be a “major barrier” (P12) to uptake of LAB.
One health professional described the following incident,
which he emphasized was “not uncommon” (P12):
I just had a young lady who is not confirmed
rheumatic but she got Strep sores so we do the usual
bicillin. She was fine in the room with me, but when she
went out to the nurse she took off down the street. (P12)
Another health professional explained their responsi-
bility for administering LAB injections in a way that
minimizes patients’ pain and increases the chance of
patients adhering to treatment uptake. As the health
professional explained, “the injection itself is one of the
most painful we can give and if they [patient] have had
a bad experience [with LAB injections] they are less
likely to turn up for another one” (P19).
Further to the above comment, one health professional
described how health care professionals also witness
parents’ anguish at seeing their child in pain and strug-
gle themselves with inflicting pain.
I think it’s just one of those horrible, painful injections
that children don’t like, so their parents find it difficult
when their child’s kicking up such a stink about, to
bring them in. They don’t want to see them have pain.
Even though we know we talk with parents; they
understand it’s for their heart, they understand it’s for
good. But to try and sit on a child and give a horrible
injection is very traumatic to the nurse as well. […] It’s
a very horrible thing for staff to go through. (P18)
While health professionals clearly emphasise pain as a
barrier to LAB uptake, it is not so clearly emphasised by
patients and parents/carer givers. Interview data suggest
that in some instances the issue of pain associated with
LAB injections diminishes over time. One mother ex-
plained that after seven years of receiving treatment her
daughter is now used to the pain.
She’ll know what to do. She’ll get on the bed and lay
there […] She knows, when they ask her, which side she
last had. She says, “Yes, I’ll have it on this side”. (P6)
Similarly, young adult patients explained that after
years of receiving treatment they had “got used to [the
pain]” (P7).
In contrast, the mother of a 15 year old, who has been
receiving treatment for five years, explained that the
after-pain of LAB injections remains an issue for her
son. “He doesn’t want to go. He doesn’t want to go and
most of the time he doesn’t want to go because he com-
plains about the after-pain” (P22). Despite health profes-
sionals using ice-packs before treatment, this participant
explained that her son experiences pain for an hour after
receiving an injection.
Locus of responsibility
For parents, the pain associated with LAB injections is
intrinsically linked to locus of responsibility. The an-
guish of seeing children in pain, as described above,
makes it difficult for parents to assume responsibility for
treatment particularly when their child is unwilling to
receive it. A health professional explained, “It’s very
often extremely difficult for Mums and Dads, or any
rellies (relatives) to persuade a child to come in” (P13)
to the clinic for treatment. Another health professional
explained that when parents are confronted with a child
who “is screaming and bucking and says no, well that’s
the end of the story” (P18).
Although most parents acknowledge responsibility for
their child’s treatment, they do not feel that they can
‘force’ their child into receiving their LAB injections.
When discussing prophylaxis, the mother of a four year
old explained that for some months her daughter has
not wanted to get her injection. The participant added,
“I can’t force her to go to [the clinic to] have it if she
doesn’t want it. […] If I try to take her she’ll just go
mad” (P1). Another mother explained how she supports
her reluctant adolescent son to receive timely treatment.
“I can’t really force him to go but if I say “Okay come
on, let’s go”, then he’ll move. But I have to be there”
(P22). Finding ways to support children and adolescents
to willingly receive treatment is preferable to using the
physical force which one mother described: “When I’d
take him up there [the clinic] you’d have to have three
or four nurses to hold him down” (P4). The participant
went on to explain that three years after being diag-
nosed, her 11 year old son “is really good at it now”
(P4). But that was only after she “snapped […] and cried
at the same time” and explained to him that she did not
want him to die.
Understanding the gravity of RF/RHD means that
some children, even from a young age, recognise the
importance of receiving treatment. After his mother
'snapped', the 11 year old boy referred to above under-
stood the necessity of LAB injections and now assumes
some of the responsibility for his prophylaxis. His
mother explained that now her son and his 12 year old
sibling, who also has RHD, are the ones that remind
her “most of the time” (P4) when they are due for their
injections. Similarly the mother of a 10 year old child
explained how her daughter ‘knows’ when she has missed
an injection. “She’ll say to me, “Mum, I didn’t get my in-
jection this month”” (P6).
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Interview data also highlight fundamental differences
in individual health professionals’ philosophical positions
regarding who is responsible for patients’ treatment.
Some health professionals “believe that [their] duty of
care is to the child” (P13) or to the adult patient; while
there are other health professionals who consider that
adherence to LAB treatment is the patient’s responsibil-
ity, or in the case of children and adolescents, the re-
sponsibility of parents/care givers.
Although health professionals recognize their duty of
care in providing treatment, some health professionals
believe that “[patients’] need to take up the responsibil-
ity” (P11) for their treatment. This belief was reiterated
by one health professional participant who was emphatic
that the patient’s “health is my concern, not my respon-
sibility” (P20). The same health professional added:
As a parent, my child’s health is my responsibility. […]
An adult - it’s [their] choice. […] Yes I know it [LAB
injection] hurts but it’s your health, your responsibility
in the end. We have to stop babying people and let
people make informed decisions. (P20)
Site of service delivery and facilitating access
While the locus of responsibility outlined above related
to who prompted patients to present for prophylaxis,
and how they did this, this theme did not cover where
the treatment was physically provided. Although a
number of alternate locations for service delivery were
mentioned in study interviews, the predominant site
for delivery of prophylaxis remains the primary health
care service/clinic.
An example of a non-clinic based service model was
outlined by one health professional who has previously
worked in the adjacent jurisdiction of the Northern Ter-
ritory. They explained the approach used there:
We did not wait for the community to come in, we
went out and we ticked people off the register as we
gave it [LAB injections] to them wherever it was most
convenient for them. […] Sometimes that was in the
back of a car, we used to give their bicillin. It was
extremely well accepted. (P13)
In the Northern Territory, delivering treatment in
some communities is often linked to the full-moon cycle.
While this is longer than the recommended 28 day interval
for LAB delivery, the longer time frame (and theoretical
increased risk of having a recurrent episode of RF) is
rationalized by a belief that this program enhances
patient-mediated recall. Nonetheless, it seems this ap-
proach is used more to prompt clinical staff rather than
to facilitate patient self-presentation.
All the clinics had the full moon calendar and off they
go every month. [Nurses go] out with the health worker
and some community workers and jab as many people
as possible. (P12)
The health professional quoted above considers the
full-moon approach “a little bit paternalistic” but added
that it results in “about a 90 % success rate” (P12). For
this health professional, the challenge of LAB uptake is
finding a balance between paternalistic approaches,
which result in higher uptake, and a “self-empowerment
through education approach” (P12), which he estimated
results in uptake rates of approximately 60–70 %.
There is no evidence in the interview data that the full
moon calendar approach is used in far north Queensland
communities included in this study. However, for some
health professionals, arriving unannounced at patients’
homes is an option to ensure patients receive timely
prophylaxis, as the following health professional explained:
Do it at home, if it has to come to that. That’s the only
way you’ll get them. If you don’t get them you’ll just
have to keep pounding and pounding until they are
saying, “I give up, come on, let’s go up”. (P16)
Although it is often health professionals who instigate
delivery of treatment in the community as a mechanism
for enhancing recall, some patients, particularly children,
also reported preferring to receive prophylaxis in their
own homes. One mother organizes for her daughter to
receive treatment at home, to counteract her daughter’s
unwillingness to receive LAB injections.
A couple of times I rang them [health professionals] to
come out. But most of the time they just normally
come out and give it [LAB injection] because they
know what she’s like (P1).
Health professionals are also alert to opportunities of
‘catching’ patients who are overdue for their prophylaxis
when they present to the health service for other rea-
sons. The following comments provide examples of
opportunistic delivery:
I had one lot one day, the police brought him in
because he’d fallen over and hurt himself at football.
What was - he’s about 10? He hadn’t had his injection
for months and I said to him, “Do you want to have
it?” and he said, “Yes, I will.” His mate held his hand
while he had his needle (P20).
When they’re coming in for a cold or something else
and I’m seeing them, I say, “Look, your injection’s due.
You happy for me to give it?” (P19)
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In addition to opportunistic delivery, an additional
strategy for enhancing delivery is providing the ancillary
services that enhance health service access. An identified
key component of such support is transport to and from
the health service. One clinical service included in this
study supports a community bus that has scheduled
hourly services to transport patients for appointments.
Other clinics organize individual patient transfers to and
from the clinic, particularly for patients who are at risk
of not attending appointments. One health professional
described a range of situations in which patients are pro-
vided individual transport:
…like with the really dysfunctional families and if the
children are quite young, we would go out and get
them if necessary, particularly when there are other
factors why they might not be turning up. So if it’s
really, really hot or if it’s just torrentially raining, you
can’t expect them to sort of walk up with young
children, particularly if they live on [the other side] of
town. We’d go and get them. You know, just offer a
little assistance like that. (P21)
Education
In order for patients and care givers to make informed
decisions regarding LAB prophylaxis it is necessary for
them to have access to information about RF/RHD and
to gain an understanding of factors such as symptoms,
treatment and the implications of not receiving prophy-
laxis. Health professionals consider that patient and parent
education relating to RF/RHD is important. Although
educational material such as patient booklets and elec-
tronic resources are available and accessible to clients,
health professionals in the study highlight the need to
“revisit” (P14) information and educational messages
with patients and their families on a regular basis. One
health professional was particularly adamant about the
need to educate patients and parents:
I think the parents need to be sat down and have a
good talk to about what RHD is or what happens if
you don’t have the injections, or what happens if you
do get Strep. […] In the community we need to put
more education into learning about heart disease. I see
it as a must. […]. Parents need to be educated. That’s
the only way the kids can be educated; if the parents
know. We need to really get in their ears - parents need
to bring their kids up here to get their injections. (P15)
The same health professional also highlighted the lack
of public health messages focusing on RF/RHD and a
lack of community understanding of the impacts of the
disease. During interview the health professional com-
mented on the extent of public health messages about
diabetes and sexually transmitted diseases and con-
trasted this to the absence of RF/RHD messages, which
he believes should be equally as important. “If we can go
out there and talk about STIs or diabetes or renal dis-
ease out in the open we should start talking about RHD”
(P15). The health professional further commented on
what he perceives as a key underlying issue:
in our community, if someone dies of RHD the
community doesn’t see it as a problem or a medical
issue; they blame other things outside of that. But that
makes it difficult when you’re trying to get the word
out there to people in the community. […] We need to
stand up and talk and get that out there and tell them
that actually a serious thing is happening. (P15)
Patients do not necessarily make a connection between
some of the symptoms of RF, such as sore throats or
joint pain, and the disease. Providing patients with edu-
cation is a means of patient “self-empowerment” (P12)
and health professionals are well positioned to support
patient education. For health professionals to be able to
educate and influence patients, they themselves need to
be educated about RF/RHD. One health professional ex-
plained that when she started working in the community
she “didn’t even know the difference between rheumatic
fever and rheumatic heart disease” (P11). The opportunity
to attend training workshops enabled this health profes-
sional to learn more about these conditions and to under-
stand “the importance of why these people are having
injections” (P11). While health professionals are typically
committed to patient education, there are some who
believe that this is subsidiary to the issue of personal
responsibility and locus of responsibility outlined above:
“unless people take ownership of what it is – that goes for
any disease, any medication – all the education in the
world won’t do anything” (P18).
Health professional-patient relationships
Health professionals, who establish trusting relationships
with patients, particularly children, feel that they are able
to influence prophylaxis uptake. Establishing relation-
ships, however, is noted to be dependent on continuity
of health professionals, which in remote communities is
not always possible, as the following health professional’s
comment highlights:
there is such a turnover of staff in places like this that
they [patients] don’t get a chance to get to know you.
People don’t come to these places and stay long. […]
Knowing the staff makes a difference […] the
continuity of the face, because they [patients] start to
trust you. They’re comfortable coming to [someone
they know] (P20).
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Having the same health professional administer LAB
injections each time also enables patients to “know the
technique” (P21) that the health professional uses. Being
familiar with a health professional’s technique and trust-
ing the health professional enables a better patient treat-
ment experience, for an otherwise “horrible, painful
injection” (P18). When health professionals are able to
take the time to establish relationships with patients “it’s
easier for the patient to approach the clinic to have their
injection – they can see a friendly face” (P18). Support-
ing the health professional’s remark was a comment by a
patient, who named the particular health professional
she prefers; “I like it when […] gives it. She’s friendly and
she does it gently” (P9).
Creating rapport with a patient, particularly a child, by
visiting them at home and administering the LAB injec-
tion in a setting where they feel comfortable is conducive
to ensuring timely uptake of treatment. The positive out-
comes of establishing trusting health professional-patient
relationships are highlighted in the following comments:
one of the nurses here who has actually established a
really good relationship with a nine-year-old who was –
who initially it took two hours to convince to have her
bicillin for her confirmed rheumatic heart. Now, just
whenever [the nurse] visits her at home, she happily rolls
over and lets her give it to her without any complaints.
So, it’s definitely a good time and explanation and
relationship development on all of that. (P12)
You know, even if you fail to give the injection the first
time, you go and you have a bit of a yarn, and you say
what it’s for and get to know them, and particularly
say, “Where would you like to have it, have you got a
bedroom?” You know, because the first few times I
went out, [to the client’s house] I was expected to give
it on the couch in front of everybody, including the
dogs. I said, no, this is not okay, and kids need privacy
too. So, I think really it’s that rapport of just getting to
know the children particularly. (P13)
Although some health professionals and patients con-
cede that establishing a relationship between them sup-
ports the experience of receiving LAB injections, one
patient explained that her relationship with health profes-
sionals administering treatment was of no importance. For
this 23 year old, having a good relationship with clinical
staff “doesn’t matter”. The participant elaborated, “I just
think about my health” (P10). Similarly, another adult pa-
tient explained that it “doesn’t matter” (P8) for him which
health professional administers his LAB injection. These
participants’ comments suggest that establishing health
professional-patient relationships is more important
when the patient is a child.
Discussion
This study provides important insights into why systems
for secondary prophylaxis delivery for RF/RHD may, or
may not, be effective. While findings offer perspectives
from patients, families and health professionals in one
region of Australia, it is likely the issues highlighted here
will be valuable to broader Australian and international
audiences including health practitioners and policy makers.
In a previously conducted literature review of secondary
antibiotic prophylaxis for RF/RHD, Remond et al. [12] ex-
amined the delivery of LAB within Wagner’s Chronic Care
Model (CCM) framework because of the longevity of
prophylaxis required for RF/RHD patients, the low uptake
of treatment, and the complexity of delivering health care
in this context. Wagner’s CCM encompasses a broad
whole-of-system approach that incorporates patient, pro-
vider and system-level interventions and has been used as
a framework for a broad range of communicable and non-
communicable chronic diseases [19]. In Fig. 1, we use this
framework to schematically conceptualize and represent
our study results. The following discussion contextualizes
our study findings within the CCM components of clinical
practice, community resources and policy, and productive
interactions.
Clinical practice consists of four components: infor-
mation systems, decision support, delivery system design
and self-management support. Case ascertainment and
registration and reminder/recall systems are important
to supporting the delivery of LAB prophylaxis and con-
stitute information systems and decision support in the
CCM. Evidence [20] suggests that providing numerous
Fig. 1 Applying the findings of Sharing Success (in italics) to the
Chronic Care Model
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reminders and using a range of methods to remind pa-
tients is effective in improving uptake of regular health
treatments.. Findings from our study provide evidence
that health providers use a range of initiatives to remind
patients about upcoming and overdue LAB prophylaxis.
Patients and parents/care givers do acknowledge the
usefulness of such reminders, however, the extent to
which these strategies are successful in influencing up-
take is unclear.
Within the context of information systems, our findings
also demonstrate that multiple systems are used at study
sites to facilitate LAB registration and recall. This redun-
dancy highlights opportunities for enhancing consistency
and simplicity in systems. While study findings do not ex-
plain why multiple systems are in place, the requirement
of duplicate data entry to a variety of databases, and on-
going use of local registers, suggests that regional RF/RHD
register and recall systems do not provide sufficient func-
tionality for local health care services. However, the need
for regional databases is evident as failure to track patients
across multiple systems and a lack of conformity between
health service delivery sites, particularly in remote areas
characterized by high staff turnover, are both likely to
undermine LAB recall and delivery.
Addressing perceived issues about pain of injections
forms part of delivery system design as identified in the
CCM. Although study findings clearly demonstrate that
health professionals perceive pain as a barrier to LAB
uptake, the evidence is not so clear from the patients’/
parents’/care givers’ perspectives. The interrelationship
of pain with other factors is reflected by Harrington et
al. [21], who contend that the pain associated with LAB
injections has no simple relationship with uptake of sec-
ondary antibiotic prophylaxis. Regardless of the differing
perspectives of pain as a barrier to uptake, interview data
indicates that reducing the pain associated with delivery
of secondary antibiotic prophylaxis delivery is important
to patients, parents/care givers and health professionals.
Study findings present a range of initiatives used to re-
duce pain, however whether or not these initiatives are
successful is not evident. The limited evidence available in
the literature suggests that mixing lidocaine with LAB [22]
and using a vibrating device together with a cold pack [23]
can reduce the pain associated with administration. Earlier
studies also suggest that offering choices to patients may
engender perceptions of control that in return can reduce
the pain of injections [24]. Thus, in situations where pain
is highlighted as an issue impeding delivery of LAB, it may
be important for clinicians to enhance perceptions of cli-
ent control as well as offering pain-relieving options.
Our study findings position locus of responsibility within
the CCM component of self-management support. The
dynamic tension of responsibility linking patient/care
giver and health professional is highlighted. Parents and
care givers of patients requiring secondary prophylaxis ac-
knowledge responsibility for ensuring adherence to treat-
ment regimes, yet are reticent to ‘force’ children to receive
treatment. Tension similarly exists among health profes-
sionals. A previous Australian study [21] found that there
is a conflict for health professionals between “providing
comprehensive health care and respecting patients’ auton-
omy”. This finding is reflected in our study, which demon-
strates differences in health professionals’ perspectives
regarding who is responsible for patients’ treatment. In
spite of such tensions, both studies highlight that feeling
cared for and nurtured and having a sense of belonging to
a health service are important determinants of increased
uptake of LAB for patients.
Decisions as to where LAB injections are delivered,
constitute delivery system design under the CCM. The
importance of local health service delivery reaching
into the community is highlighted in this and previous
studies [25, 26]. In the case of LAB delivery, linking
with the community extends beyond stakeholder, care
giver and patient engagement to actual physical delivery of
care outside the confines of the clinic. The benefit of
community-based delivery is supported by the experience
of one LAB delivery program in Auckland, New Zealand.
This program focused on community nurses delivering
LAB injections in schools and demonstrated high levels of
delivery ranging from 80 to 100 % of required doses [27].
While providing intramuscular injections of antibiotics
in a community, school or home setting may be daunt-
ing to an uninitiated health care provider this can, and
is, safely achievable. The possibility of anaphylaxis can
be of particular concern but the risk is low [28]. Practical
considerations including delivering the first dose within
the primary health care clinic or hospital, providing
appropriate training to staff and having supplemental
oxygen and adrenaline available when providing care
in the community are usually sufficient to manage any
risk of an allergic reaction or syncope/faint.
Education is a key component of improving chronic
disease care and can be envisaged as falling under a number
of components of the CCM: community resources and pol-
icy, informed empowered patients, and prepared proactive
health team. While study results identify education as a key
factor in LAB delivery, interviews highlight a diverse range
of target audiences including patients, parents/care givers
and health professionals. Often the initial target for health
education is care givers. As patients become older and de-
velop greater autonomy, the focus of education transitions
to the patients themselves. Given many patients requiring
LAB prophylaxis in this study are children, it is not sur-
prising that much of the commentary relates to health
professionals educating parents/care givers. Educating care
givers supports better understanding of the importance of
prophylaxis and encourages them to take control of their
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childrens’ health. Nonetheless many parents/care givers
noted that their role is to utilize educational information
to in turn educate and influence their child’s behavior.
Given that LAB prophylaxis delivery must be continued
into adolescence and beyond, focusing only on care givers
fails to address this important stage of transition between
child-care giver dependency and adulthood. While this is
obviously important, how adolescents’ perceptions and
needs differed regarding LAB was not captured in this
study. Given this remains a high-risk period for both RF
recurrence and RHD development and progression, this
should be a particular focus for future study.
Health professional-patient relations (productive inter-
actions in the CCM) are a fundamental element of
health care delivery. How relations might be enhanced,
particularly in linguistically and culturally diverse set-
tings exemplified by remote Indigenous Australian com-
munities, is complex. Key elements are likely to include
community perceptions of ownership and control of
local health care services. A previous Canadian study by
Chandler and Lalonde [26] demonstrates the importance
of cultural continuity and community ownership and con-
trol on patient mental health outcomes. The importance of
such ownership and engagement, as exemplified by formal
Aboriginal community-controlled health organizations or
less formal engagements between health services and com-
munities, was highlighted in the study and is likely to be
similarly important in enhancing LAB uptake.
Study limitations
The use of snowball sampling in the study meant that
the size of the sample was reliant on the key informants
and study participants to recommend and approach sub-
sequent participants. It is therefore difficult for the re-
searchers to ascertain whether study data is indicative of
enablers and barriers to the uptake of secondary prophy-
laxis in other remote communities in Australia. Study
findings, however, highlight issues that will be valuable
to broader Australian and international audiences, in-
cluding policy makers.
Conclusions
Delivery of secondary antibiotic prophylaxis for RF/RHD
remains a priority for reducing the impact of this pre-
ventable cause of heart disease both in Australia and
globally. This study highlights that a number of barriers
persist to achieving optimal uptake of LAB in remote In-
digenous Australian communities including deficits in
existing registration and recall systems, the pain of injec-
tions, and varying perceptions of locus of responsibility.
It also highlights a number of enablers to improving up-
take including: supporting patient autonomy; education
of patients, care givers and healthcare professionals;
positive patient-health professional relationships; and
supporting systems for community-based outreach and
service delivery.
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Recommendations arising from this study include:
Further investigation regarding what functionality would be required
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on patients transitioning from child-care giver dependency to
adulthood.
Implementing pain-relieving strategies when delivering LAB, where
considered necessary.
Consideration of community-based delivery of LAB and/or provision of
community transport, where appropriate.
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